Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Idoform Travel
- Development stage
- Unknown
- Lead developer
- Ferrosan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Idoform Travel is a multi-strain probiotic dietary supplement formulated to support gastrointestinal health and maintain a balanced intestinal microbiome, particularly during travel. It typically contains a proprietary blend of four probiotic strains: *Lactobacillus rhamnosus* GG (LGG), *Bifidobacterium animalis* subsp. *lactis* (BB-12), *Lactobacillus acidophilus* (LA-5), and *Streptococcus thermophilus* (TH-4 or STY-31). These bacteria work by colonizing the gut, enhancing the mucosal barrier, and modulating the local immune environment to prevent the overgrowth of pathogenic organisms. While commercially available as a nutraceutical for the prevention of traveler's diarrhea, it has been investigated in clinical trials (such as NCT04241029) as an adjuvant therapy for patients with ulcerative colitis who show an insufficient response to anti-TNF biologics, aiming to improve clinical response by altering the gut microbiota and cytokine production.
- Brand names
- Idoform TravelIdoform Rejse
- Other names
- IDOFORM Travel Probiotic
Beyond the preview
Go deeper on Idoform Travel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Idoform Travel.